DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo


company name or ticker

Achillion Pharmaceuticals Could Hang With The HCV Big Boys

All You Need To Know About HCV From The EASL Conference This Weekend

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs

These three clinical stage biotech companies are working on therapies addressing billion dollar indications.

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

The Biotech Stocks JMP Is Watching

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals

Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?

Achillion Pharmaceuticals' ACH-3102 and ACH-3422 could eventually offer up an alternative to Gilead Sciences' HCV medicines.

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape
See More Articles...